T. Rowe Price's 8.2% passive stake adds a major institutional holder to the base. Monitor future 13G amendments for any stake changes and watch for any 13D conversion if the holder's intent shifts, though the filing explicitly disclaims activist purpose.
XENE drugs
XENE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $39.17entry
- T+1 · 8d ago +3.27%α +0.90% · $40.45
- T+5 · 4d ago +3.34%α +0.75% · $40.48
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
T. Rowe Price Investment Management filed a Schedule 13G disclosing a 8.2% passive stake in Xenon Pharmaceuticals as of September 30, 2026, representing 7,905,757 shares. This is a new 13G filing by T. Rowe Price, indicating a significant passive institutional position in the biotech company.
Key Financial Metrics
Key Facts
- T. Rowe Price Investment Management disclosed beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals common stock as of September 30, 2026
- The stake represents 8.2% of outstanding shares
- The filing is a new Schedule 13G, not an amendment
- T. Rowe Price certifies passive intent under Rule 13d-1(b)
- Sole voting power is held over 7,558,551 shares; sole dispositive power over 7,905,757 shares
Financial Impact
8.2% stake valued at approximately $312 million based on $3.8B market cap
Risk Factors
- No stated intent to influence management or strategy
- Passive filing; stake could be reduced without public notice until next threshold
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001897612-26-000699 |
| Document: 0001897612-26-000699-index.html | 0001897612-26-000699 |
| Document: 0001897612-26-000699.txt | 0001897612-26-000699 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Viewing Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers